Cancer Research

# IkB Kinase $\alpha$ Is Required for Development and Progression of *KRAS*-Mutant Lung Adenocarcinoma



Malamati Vreka<sup>1,2</sup>, Ioannis Lilis<sup>1</sup>, Maria Papageorgopoulou<sup>1,2</sup>, Georgia A. Giotopoulou<sup>1,2</sup>, Marina Lianou<sup>1</sup>, Ioanna Giopanou<sup>1</sup>, Nikolaos I. Kanellakis<sup>1</sup>, Magda Spella<sup>1</sup>, Theodora Agalioti<sup>1</sup>, Vasileios Armenis<sup>1</sup>, Torsten Goldmann<sup>3</sup>, Sebastian Marwitz<sup>3</sup>, Fiona E. Yull<sup>4</sup>, Timothy S. Blackwell<sup>4</sup>, Manolis Pasparakis<sup>5</sup>, Antonia Marazioti<sup>1</sup>, and Georgios T. Stathopoulos<sup>1,2</sup>

# Abstract

Although oncogenic activation of NF $\kappa$ B has been identified in various tumors, the NF $\kappa$ B-activating kinases (inhibitor of NF $\kappa$ B kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKK $\alpha$  and IKK $\beta$  in *KRAS*-mutant lung adenocarcinomas induced by the carcinogen urethane and by respiratory epithelial expression of oncogenic *KRAS*<sup>G12D</sup>. Using NF $\kappa$ B reporter mice and conditional deletions of IKK $\alpha$  and IKK $\beta$ , we identified two distinct early and late activation phases of NF $\kappa$ B during chemical and genetic lung adenocarcinoma development, which were characterized by nuclear translocation of *Rel*B, I $\kappa$ B $\beta$ , and IKK $\alpha$  in tumor-initiated cells. IKK $\alpha$  was a cardinal tumor promoter in chemical and genetic *KRAS*-mutant lung adenocarcinoma, and respiratory epithelial IKK $\alpha$ -deficient mice were

# Introduction

Tumors harboring mutations in the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (*KRAS*) are notoriously resistant to current treatments (1). Lung adenocarcinoma (LADC), the

**Corresponding Authors:** Georgios T. Stathopoulos, University of Patras, Basic Biomedical Sciences Research Building, 2nd Floor, 26504 Rio, Greece. Phone: 302610969155; Fax: 302610997215; E-mail: gstathop@upatras.gr; and A. Marazioti, amarazioti@upatras.gr

doi: 10.1158/0008-5472.CAN-17-1944

©2018 American Association for Cancer Research.

www.aacrjournals.org

markedly protected from the disease. IKK $\alpha$  specifically cooperated with mutant *KRAS* for tumor induction in a cell-autonomous fashion, providing mutant cells with a survival advantage *in vitro* and *in vivo*. IKK $\alpha$  was highly expressed in human lung adenocarcinoma, and a heat shock protein 90 inhibitor that blocks IKK function delivered superior effects against *KRAS*-mutant lung adenocarcinoma compared with a specific IKK $\beta$  inhibitor. These results demonstrate an actionable requirement for IKK $\alpha$  in *KRAS*mutant lung adenocarcinoma, marking the kinase as a therapeutic target against this disease.

**Significance**: These findings report a novel requirement for IKKα in mutant *KRAS* lung tumor formation, with potential therapeutic applications. *Cancer Res;* 78(11); 2939–51. ©2018 AACR.

number one cancer killer worldwide (2), harbors *KRAS* mutations in up to 30% to 40% of the cases diagnosed in Europe and North America (3). A cardinal mechanism of *KRAS* mutation–associated drug resistance appears to be the oncogene's addiction to transcriptional programs that facilitate sustained tumor-initiated cell survival, such as NF $\kappa$ B (4). To this end, mutant *KRAS* was recently shown to interact with NF $\kappa$ B–activating kinases [inhibitor of NF $\kappa$ B (I $\kappa$ B) kinases, IKK] to promote cancer cell survival, stemness, and drug resistance (5, 6).

NFκB is activated via the canonical (involving IκBα, IKKβ, and *Rel*A/P50) and noncanonical (comprising IκBβ, IKKα, and *Rel*B/P52) pathways (7). We and others previously documented NFκB activation in murine and human LADC (8–10). However, the IKKs responsible for this remain elusive, and most studies focused on IKKβ, IKKε, and TANK-binding kinase 1 (TBK1; refs. 11–14). IKKα participates in both canonical and noncanonical NFκB pathways and cooperates with IKKβ for tumor cell growth *in vitro* (11, 15), but its role in LADC development *in vivo* is uncharted.

We deployed NF $\kappa$ B reporter and conditional IKK $\alpha$ - and IKK $\beta$ -deleted mice to decipher the timing of NF $\kappa$ B activation and the mutual impact of IKK $\alpha$  and IKK $\beta$  on LADC development. In mouse models of tobacco carcinogen- and oncogenic *KRAS*<sup>G12D</sup>-triggered LADC, IKK $\alpha$  was cardinal for disease initiation and progression. Moreover, IKK $\alpha$  selectively fostered cellular proliferation in the context of mutant *KRAS* and was also highly expressed in human LADC. Importantly, dual IKK $\alpha$  /IKK $\beta$ 



<sup>&</sup>lt;sup>1</sup>Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece. <sup>2</sup>Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), University Hospital, Ludwig-Maximilians University and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany. <sup>3</sup>Clinical and Experimental Pathology, Research Center Borstel, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germany. <sup>4</sup>Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. <sup>5</sup>Mouse Genetics and Inflammation Laboratory, Institute for Genetics, University of Cologne, Cologne, Germany.

**Note:** Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

M. Vreka, I. Lilis, and M. Papageorgopoulou share first authorship of this article.

A. Marazioti and G.T. Stathopoulos share senior authorship of this article.

inhibition yielded promising results against *KRAS*-driven LADC, lending hope for translational applications of our findings.

# **Materials and Methods**

Additional Methods are described in the Online Supplement.

## Mice

C57BL/6J (#000664), FVB/NJ (#001800), B6.129(Cg)-Gt (ROSA)26Sor<sup>tm4</sup>(ACTB-tdTomato.-EGFP)Luo</sup>/J (mT/mG; #007676; ref. 16), B6.129S4-Kras<sup>tm4Tyi</sup>/J (LSL.KRAS<sup>G12D</sup>; #008179; ref. 17), NOD. CB17-Prkdc<sup><scid></sup>/J (NOD/SCID; #001303), and FVB.129S6(B6)-Gt(ROSA)26Sor<sup>tm1(Luc)Kael</sup>/J (LSL.R26.Luc; #005125; ref. 18) mice were from The Jackson Laboratory. NFkB reporter mice (NGL; NF-kB.GFP.Luciferase), B6.B4B6-Chuk<sup><tm1Mpa></sup>/Cgn (Chukf/f), and B6. B4B6-Ikbkb<sup><tm2.1Mpa></sup>/Cgn (Ikbkbf/f), B6;CBA-Tg(Scgb1a1-cre) 1Vart/Flmg (Scgb1a1.Cre), and Tg(Sftpc-cre)1Blh (Sftpc.Cre) mice have been described (8, 19–21). Mice were bred >F9 to the C57BL/6 and/or FVB backgrounds at the University of Patras Center for Animal Models of Disease. The number of mice used for these studies (n = 542) is detailed in Supplementary Table S1.

#### Reagents

Urethane (CAS#51-79-6) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were from Sigma, adenoviruses from the Vector Development Lab of the Baylor College of Medicine (Houston, TX), D-luciferin from Gold Biotechnology, HEK293T cells from ATCC, and Lewis lung carcinoma (LLC) and A549 lung adenocarcinoma cells from the NCI Tumor Repository (Frederick, MD). Primers and antibodies are listed in Supplementary Tables S2 and S3. Lentiviral shRNA pools (Santa Cruz Biotechnology) are described in Supplementary Table S4.

#### Mouse models of LADC

Chemical-induced LADC was induced in *FVB* and *C57BL/6* mice, respectively, by a single or by 10 consecutive weekly intraperitoneal exposures to 1 g/kg urethane (8, 22–24). *KRAS*<sup>G12D</sup> driven LADC was induced via intratracheal injections of  $5 \times 10^8$  plaque-forming units (PFU) adenovirus type 5 encoding CRE recombinase (Ad-*Cre*) to *LSL.KRAS*<sup>G12D</sup> mice on the *C57BL/6* background (9, 17). *NOD/SCID* and *C57BL/6* mice were anesthetized by isoflurane and received  $2 \times 10^6$  HEK293T and  $0.5 \times 10^6$  tumor cells into the rear flank, and vertical tumor diameters ( $\delta$ ) were measured and mice were imaged for bioluminescent detection of cell mass weekly thereafter. Cell spot volume (V) was calculated as V =  $\pi \times (\delta 1 \times \delta 2 \times \delta 3)/6$ , and mice were killed after 6 weeks. Flank tumors were harvested and fixed with 4% paraformaldehyde or processed for immunoblotting.

#### Drug treatments

*LSL.KrasG12D;LSL.R26.Luc* mice received  $5 \times 10^8$  PFU intratracheal Ad-*Cre*, followed by daily intraperitoneal injections of 100 µL saline or 0.5 mg/Kg TPCA-1 or 17-DMAG in 100 µL saline at days 14 to 28 or 84 to 112 after Ad-*Cre*. Mice were imaged for bioluminescent detection of LADC burden at 0, 14, 28, 84, and 112 days after Ad-*Cre*. Mice were sacrificed and lungs were harvested at 112 days after Ad-*Cre*.

#### Cellular assays

Mouse primary lung adenocarcinoma cells and airway epithelial cells were derived from the lungs of urethane (single dose 1 g/kg) or saline-treated FVB or C57BL/6 mice by simple tumor or large airway dissection or epithelial stripping, respectively, and 5month or 5-day culture, respectively, as described elsewhere (25). These cell lines were named XYLA#, with X signifying the mouse strain (F, FVB; C, C57BL/6), Y the carcinogen used (U, urethane), LA lung adenocarcinoma, and # their serial number by derivation date. Cells were cultured at 37°C in 5% CO<sub>2</sub>-95% air using DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine, 1 mmol/L pyruvate, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were tested biannually for identity (by the short tandem repeat method) and for Mycoplasma spp. (by PCR). For experiments, frozen cells were reconstituted and were passaged 2 to 5 times for less than 2 weeks. In vitro cancer cell proliferation was determined using the MTT assay. For this,  $2 \times 10^4$  cells/well were plated onto 96-well plates. Daily thereafter, 15 µL of 5 mmol/L MTT working solution in PBS was added to wells to be measured that day. The plate was incubated for 4 hours at 37°C in a 5% CO<sub>2</sub> humidified incubator, followed by the addition of 100 µL acidified isopropanol per well for sediment solubilization and absorbance measurement at 492 nm on an MR-96A photometer (Mindray). For soft-agar colony formation assay,  $7.5 \times 10^3$  cells were plated in 60-mm culture vessels in semisolid 0.7% agarose in full culture medium and were incubated for 30 days at 37°C in a 5% CO<sub>2</sub> humidified incubator. Fresh culture medium (2 mL) was added to each vessel biweekly. After incubation, 500 µL MTT working solution was added to each vessel and plates were dried, inverted, photographed, and colonies were counted, as described elsewhere (25).

#### Human samples

Matched tumor and normal lung tissue RNA and sections of 23 and 35, respectively, previously reported patients with LADC from Institution 3 were used for microarray and immunohistochemistry for IKK $\alpha$  and IKK $\beta$  (26). Human studies were approved *a priori* by the ethics committee of the University of Lübeck, Germany (approval #AZ 12-220) and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from all patients. IKK score was 0, 1, 2, or 3 for no, cytoplasmic only, cytoplasmic and nuclear, and nuclear only immunoreactivity, respectively (modified from ref. 11).

#### Statistical analysis

Sample size (*n*; always biological) was determined using G<sup>\*</sup>power (http://www.gpower.hhu.de/), assuming  $\alpha = 0.05$ ,  $\beta = 0.05$ , and d = 1.5. Data were acquired by two blinded readers, reevaluated if >20% deviant (no data were excluded), examined for normality by the Kolmogorov–Smirnov test and presented as median (interquartile range) or mean  $\pm$  SEM. Differences in frequencies were examined by Fisher exact/ $\chi^2$  tests, in means of normally distributed variables by *t* test or one-way ANOVA/ Bonferroni posttests, and in medians of nonnormally distributed variables by *t* tests. Survival and flank tumor volumes were examined by Kaplan–Meier estimates/log-rank tests and two-way ANOVA/ Bonferroni posttests. Probability (*P*) is two-tailed; *P* < 0.05 was considered statistically significant. Statistics and plots were done on Prism v5.0 (GraphPad).

#### Study approval

All animal experiments were approved *a priori* by the Veterinary Administration of Western Greece according to a full and detailed protocol (approval #276134/14873/2). Male and female mice were sex-, weight (20–25 g)-, and age (6–12 weeks)-matched. Human studies were approved *a priori* by the ethics committee of the University of Lübeck, Germany (approval #AZ 12-220).

# Results

## NFkB is activated in KRAS-mutant LADC

To map pulmonary NFkB activity during KRAS-driven neoplasia, NF $\kappa$ B reporter mice (*NGL*) on the carcinogen-susceptible FVB background expressing NFkB-driven Photinus Pyralis luciferase (LUC) in-frame with EGFP (8, 23) received a single intraperitoneal injection of saline or the tobacco carcinogen urethane (1 g/kg) and were serially imaged for bioluminescence. Urethane causes respiratory epithelial Kras<sup>G12V/Q61R</sup> mutations and progressive inflammation, hyperplasias, adenomas, and adenocarcinomas in FVB mice (22-25) that in this experiment also expressed the NGL reporter (Fig. 1A and B). In addition to the baseline signals of these mice, markedly increased light emission from the chest was exclusively detected in urethane-treated mice at early and late time points corresponding to carcinogen-induced inflammation and LADC, respectively (8). Enhanced NFkB activation indicated by the EGFP reporter emanated exclusively from LADC (Fig. 1C-F). In a second approach, NGL mice were intercrossed with mice carrying a conditional loxP-STOP-loxP.KRAS<sup>G12D</sup> allele (LSL.KRAS<sup>G12D</sup>; ref. 17), and NGL and NGL;LSL.KRAS<sup>G12D</sup> offspring (all C57BL/6 background) received intratracheal Ad-Cre and were longitudinally imaged. In LSL.KRAS<sup>G12D</sup> mice, progressive inflammation, hyperplasia, adenomas, and adenocarcinomas carrying the KRAS mutation are inflicted by Ad-Cre (9, 17). To titrate Ad-Cre, mT/mG CRE reporters that switch from membranous Tomato (mT) to EGFP (mG) fluorescence upon CRE recombination (16) received 0,  $5 \times 10^7$ ,  $5 \times 10^8$ , or  $5 \times 10^9$  PFU intratracheal Ad-Luc or Ad-Cre and were killed upon subsidence of transient Ad-mediated transgene expression at 2 weeks after injection (27). The low, intermediate, and high Ad-Cre titers, respectively, caused infrequent, stochastic, and ubiquitous respiratory epithelial recombination (Supplementary Figs. S1A and S1B). We selected  $5 \times 10^8$  PFU Ad-Cre to stochastically induce recombination into the respiratory epithelium of NGL and NGL; LSL.KRAS<sup>G12D</sup> mice (Supplementary Fig. S1C). Similar to the urethane model, two phases of enhanced chest light emission by NGL;LSL.KRAS<sup>G12D</sup> but not NGL mice were observed, coinciding with early inflammation and late LADC development (8, 22-24, 28). Again, NFKB-dependent EGFP expression was confined to LADC (Supplementary Fig. S1D-S1G). These data demonstrate biphasic pulmonary NFKB activation during KRAS-driven LADC development.


# *KRAS*-mutant LADC displays both canonical and noncanonical NFκB activity

To investigate the NFκB pathway at play during *KRAS*-mutant inflammation, hyperproliferation, and LADC formation, the immunoreactivity of nuclear and cytoplasmic protein extracts of whole lungs of urethane-treated *FVB* mice and of Ad-*Cre*-treated *LSL.KRAS*<sup>G12D</sup> mice for NFκB subunits, kinases, and inhibitors were probed longitudinally (Fig. 2A–D). In the urethane model, marked Rel*B* and Rel*A* immunoreactivity was detected in nuclear extracts and enhanced IκBα, IκBβ, IKKα, IKKβ, and TBK1 immunoreactivity in cytoplasmic extracts of the neoplastic stage. Some immunoreactivity was also present in early stages but their

expression peaked in tumor-bearing lungs, while no IKKE signal was evident at any time point. In the LSL.KRAS<sup>G12D</sup> model, enhanced nuclear RelB and P52 and modest RelA immunoreactivity was detected in nuclear extracts of tumor-bearing lungs, together with some cytoplasmic immunoreactivity for IkBB, IKKα, and TBK1 (120 days). In addition, some RelA, RelB, P52, ΙκΒα, ΙκΒβ, and TBK1 immunoreactivity was evident in sameday-treated lungs (0 days), some RelA, RelB, P52, IKKα, and TBK1 immunoreactivity in inflammatory and proliferative lungs (30 and 60 days), and no IKKB and IKKE signal at any stage. IKK expression patterns were corroborated using immunofluorescent detection of IKK $\alpha$ /IKK $\beta$  on lung sections of urethane-treated *FVB* and Ad-*Cre*-treated *LSL.KRAS*<sup>G12D</sup> mice at 240 and 120 days after treatment, respectively. In both models, IKKa was expressed by a significant proportion of LADC cells, while minimal IKKB expression was detectable (Fig. 2E and F). To further characterize NFkB activity of LADC, LADC cells were derived from the lungs of saline and urethane-treated FVB mice, according to established methods (Supplementary Fig. S2A and S2B; refs. 25, 29). LADC cells exhibited enhanced nuclear RelB (but not RelA) localization and activity compared with saline- and urethane-treated lungs (Supplementary Fig. S2C and S2D). Taken together, these results indicate coactivation of the canonical and noncanonical NFkB pathways in LADC.

#### Respiratory epithelial IKKa promotes KRAS-driven LADC

We next functionally assessed the role of IKK $\alpha$  and IKK $\beta$  in LADC development, utilizing conditional IKKa and IKKB genedeleted mice (Chukf/f and Ikbkbf/f) that feature loxP-flanked alleles excised upon CRE expression (19). In a first line of experiments, mT/mG CRE reporter (control), Chukf/f, and *Ikbkbf/f* mice on the urethane-resistant C57BL/6 background (8) received  $5 \times 10^9$  PFU intratracheal Ad-Cre (a titer causing recombination in ~75% of the respiratory epithelium within 2 weeks; Supplementary Fig. S1A and S1B), and were started 2 weeks thereafter on 10 weekly doses of 1 g/kg intraperitoneal urethane, a regimen that reproducibly induces LADC in C57BL/6 mice (23, 29). In this multihit model, stochastic KRAS mutations, inflammation, apoptosis, and regeneration were repeatedly inflicted across IKK-deleted and nondeleted respiratory epithelium (Fig. 3A). Interestingly, Ikbkbf/f mice displayed decreased survival during repeated urethane exposures, suggesting a role for IKKβ in epithelial repair (Fig. 3B). However, at 6 months after urethane start, IKKa-deleted mice had markedly decreased LADC incidence, multiplicity, and burden per lung compared with controls, while IKKβ-deleted mice displayed only minor reductions in tumor multiplicity but not burden (Fig. 3C-G). These experiments were replicated on Chukf/f and Ikbkbf/f mice backcrossed >F9 to the single-hit FVB model that recapitulates the mutation spectrum of human LADC and allows separate insights into the effects of IKK deletion on tumor initiation and progression via observations on LADC number and size after 6 months (8, 22-24). For this, WT control, Chukf/f, and Ikbkbf/f mice (all FVB) received 5  $\times$  10<sup>9</sup> PFU intratracheal Ad-Cre, followed by a single intraperitoneal exposure to 1 g/kg urethane (Supplementary Fig. S3A). All genotypes comparably survived single-hit urethane (Supplementary Fig. S3B). Again, Chukf/f mice developed fewer and smaller LADC compared with controls, indicating marked tumor-initiating and promoting effects of IKKa, but *Ikbkbf/f* mice displayed tumor incidence, number, size, and load closely resembling WT littermates, suggesting that the minor




#### Figure 1.

NFxB activation in urethane-induced lung adenocarcinoma. **A-F**, *NGL* mice were backcrossed > F9 to the carcinogen-susceptible *FVB* strain and received single intraperitoneal injections of saline (n = 6) or the tobacco-contained carcinogen urethane (1 g/kg; n = 7) and were imaged longitudinally for bioluminescence. **A**, Legend to respiratory epithelial cells used in schematics throughout. **B**, Schematic of experimental time course (boxes, months) and topology of NFxB-reporter (green, cytosol) versus *Kras<sup>GoliR</sup>*-mutant (red, nucleus) cells in this model. **C**, Data summary of chest bioluminescence shown as mean (points), SEM (bars), and two-way ANOVA *P* value. \*, *P* < 0.05; \*\*\*, *P* < 0.001, respectively, for urethane-treated compared with saline-treated mice by Bonferroni posttests. **D**, Representative merged bioluminescent/photographic images with pseudocolor scale showing increased chest light emission of urethane-treated mice at early and late time points after carcinogen injection (arrows). **E**, Representative images of gross lungs and hematoxylin and eosin-stained lung sections of saline-treated mice at 8 months after injection showing lung adenocarcinomas in the latter (arrows). **F**, Light-optic and green fluorescent lung images of representative urethane-treated mouse at 8 months after injection showing NFxB-driven GFP expression in lung adenocarcinomas (dashed lines).


tumor-promoting effects of IKKβ require repetitive carcinogen challenge to become evident (Supplementary Fig. S3C–S3G). *Chukf/f* and *lkbkbf/f* mice were also intercrossed with *Scgb1a1.Cre* (20) and *Sftpc.Cre* (21) CRE drivers (all *C57BL/6*) and their offspring received 10 consecutive weekly intraperitoneal injections of 1 g/kg urethane starting at 6 weeks of age (Supplementary Fig. S4A). Interestingly, both *Scgb1a1.Cre* and *Sftpc.Cre*-driven

IKKα-deletion was equally protective against LADC, while IKKβdeletion had no effect (hence pooled *Scgb1a1.Cre* and *Sftpc.Cre* data are presented; Supplementary Fig. S4B–S4E). To solidify the link between IKKα and mutant *KRAS* and to discriminate between cell-autonomous and paracrine IKKα effects, *Chukf/f* and *Ikbkbf/f* mice were intercrossed with *LSL.KRAS*<sup>G12D</sup> mice (all *C57BL/6*) and their offspring received  $5 \times 10^8$  PFU intratracheal Ad-*Cre*, a



#### Figure 2.

Increased NFkB activity and enhanced IKK $\alpha$  expression of *KRAS*-driven lung adenocarcinoma. **A**, **C**, and **E**, *FVB* mice (n = 14) received 1 g/kg intraperitoneal urethane and were sacrificed after the indicated time intervals. **B**, **D**, and **F**, Mice carrying a conditional loxP-STOP-loxP.*KRAS*<sup>G12D</sup> allele (LSL.*KRAS*<sup>G12D</sup>, *C57BL/6* strain; n = 12) received 5 × 10<sup>8</sup> intratracheal PFU Ad-*Cre* and were sacrificed after the indicated time intervals. **A** and **B**, Schematic representations of intensity and time course of inflammation, hyperplasia, and tumorigenesis in the two models (8, 20–22, 25). **C** and **D**, Immunoblots of whole lung nuclear and cytoplasmic extracts for NFkB pathway components. **C**, Note the increased expression of *Re/A*, *Re/B*, IkBB, IKK $\alpha$ , IKK $\beta$ , and TBK1 at late time points post-urethane, when lung adenocarcinomas have developed. **D**, Note the increased expression of *Re/B*, P52, and TBK1 at 4 months after Ad-*Cre*, when lung adenocarcinomas have developed. **D**, Note the increased average and were sacrificed after 8 months for fluorescent detection of IKK $\alpha$  and IKK $\beta$  immunoreactivity on cryosections of lungs with bronchi (b) and alveoli (a) and lung tumors (dashed lines). **F**, LSL.*KRAS*<sup>G12D</sup> mice (*C57BL/6* strain; n = 5) received 5 × 10<sup>8</sup> intratracheal PFU Ad-*Cre* and were sacrificed after 4 months for fluorescent detection of IKK $\alpha$  (arrows). *Rel*, v-rel avian reticuloendotheliosis viral oncogene homolog.



#### Figure 3.


Adenoviral-mediated IKK<sub>α</sub> deletion from the respiratory epithelium protects C57BL/6 mice from multihit urethane-induced lung adenocarcinoma. Conditional CRE reporter (*mT/mG*) and IKKα (*Chukf/f*) or IKK $\beta$  (*lkbkbf/f*) gene-deleted mice (C57BL/6 background) received  $5 \times 10^9$  PEU intratracheal Ad-Cre. followed by 10 consecutive weekly intraperitoneal urethane injections (1 g/kg) commenced 2 weeks after Ad-Cre and were killed 6 months later. A. Schematic of experimental time course (boxes, months) and topology of IKK-deleted (pink, cytosol) versus Kras<sup>Q61R</sup>-mutant (red, nucleus) cells in this model. B, Kaplan-Meier plot of survival with log-rank P value, ns. nonsignificant: \*. P>0.05 and P<0.05. respectively, for the indicated comparisons by the log-rank test. C, Frequency distribution of lung tumors with *n* and  $\gamma^2 P$  value, ns: \*\*. P > 0.05 and P < 0.01. respectively. for the indicated comparisons by Fisher exact test, **D-F.** Data summary of lung tumor number, mean diameter, and total volume (burden) per lung with raw data points (dots), Tukey whiskers (boxes, interquartile range; bars, 50% extreme quartiles), and Kruskal-Wallis ANOVA P values. ns, \*. and \*\*\*: *P* > 0.05. *P* < 0.05. P < 0.01, and P < 0.001, respectively, for the indicated comparisons by Dunn posttests. G, Representative images of aross lunas. Arrows. luna tumors.

model where *KRAS*<sup>G12D</sup> expression and IKK deletion coincide (Fig. 4A). Lung morphometry (30) at 4 months after Ad-*Cre* showed that IKK $\alpha$ -deleted mice had markedly decreased LADC burden compared with controls, while IKK $\beta$ -deleted mice displayed an intermediate phenotype (Fig. 4B–E). Collectively, these findings show that IKK $\alpha$  promotes *KRAS*-mutant LADC in a cell-autonomous fashion, independent from and more pronounced than IKK $\beta$ .

# IKKα selectively fosters KRAS-mutant cell prevalence *in vitro* and *in vivo*

We next stably transfected HEK293T benign human embryonic kidney cells with vectors encoding control random sequence (pC), RFP (p*RFP*), EGFP (p*eGFP*), wild-type (p*eGFP*.Kras<sup>WT</sup>), or mutant (p*eGFP*.Kras<sup>G12C</sup>) murine Kras in-frame with EGFP, and murine IKKα (p*Chuk*) or IKKβ (p*lkbkb*) in various combinations.

After transgene expression was validated, RFP-expressing control cells and EGFP-expressing intervention cells cotransfected with various combinations of  $peGFP.Kras^{WT}/peGFP.Kras^{G12C}$  and pChuk/pIkbkb were mixed at equal ratios and cocultured for 1 week, followed by quantification by fluorescent microscopy and flow cytometry (Supplementary Fig. S5A and S5B). Of note, as opposed to successful pIkbkb coexpression with  $peGFP.Kras^{WT}$ , pIkbkb coexpression with  $peGFP.Kras^{WT}$ , pIkbkb coexpression with  $peGFP.Kras^{G12C}$  and IKK $\beta$ , similar to what was previously observed with other RAS/IKB-like GTPases called  $\kappa$ B-RAS (Supplementary Fig. S5B; ref. 31). Despite this, IKK $\beta$  provided a proliferative advantage to HEK293T cells expressing  $Kras^{WT}$ , whereas  $Kras^{G12C}$ -expressing HEK293T cells proliferated more efficiently upon IKK $\alpha$  overexpression (Supplementary Fig. S5C and S5D). Subsequently, HEK293T cells were stably transfected with pCAG.Luc, followed by various




#### Figure 4.

IKKα deletion ameliorates respiratory epithelial oncogenicity of mutant *KRAS*<sup>G12D</sup>. Conditional IKKα (*Chukf/f*) or IKKβ (*lkbkbf/f*) gene-deleted mice were intercrossed with mice carrying a loxP-STOP-loxP.*KRAS*G12D conditional allele (LSL.*KRAS*G12D; all *C57BL/6*) and their offspring received  $5 \times 10^8$  PFU intratracheal Ad-*Cre* and was killed 4 months later. **A**, Schematic of experimental time course (boxes, months) and topology of IKK-deleted (pink, cytosol) versus *KRAS*<sup>G12D</sup>-mutant (red, nucleus) cells in this model, where IKK deletion and oncogenic *KRAS*<sup>G12D</sup> expression uniquely coincide in the same cells. **B**, Frequency distribution of lung tumorigenesis with *n* and  $\chi^2 P$  values. ns, nonsignificant; \*, \*\*, and \*\*\*: *P* > 0.05, *P* < 0.01, and *P* < 0.001, respectively, for the indicated comparisons by Fisher exact test. **C** and **D**, Data summary of relative lung tumor fraction and total lung tumor volume (burden) per lung with raw data points (dots), Tukey whiskers (boxes, interquartile range; bars, 50% extreme quartiles), and Kruskal-Wallis ANOVA *P* values. ns, \*, \*\*, and \*\*\*: *P* > 0.05, *P* < 0.001, respectively, for the indicated comparisons by Dunn posttests. **E**, Representative hematoxylin and eosin-stained lung tissue sections. Arrows, lung tumors.

combinations of pC, peGFP.Kras<sup>WT</sup>, peGFP.Kras<sup>G12C</sup>, pChuk, and/ or pIkbkb were validated, and two million cells were injected at different dorsal skin spots of NOD/SCID mice, followed by serial spot volume assessment and bioluminescence imaging. Again, IKKβ boosted in vivo growth of HEK293T cells expressing Kras<sup>WT</sup>, while KrasG12C-expressing HEK293T cells were rendered more tumorigenic upon IKKa overexpression (Fig. 5A-C). Interestingly, none of 8 NOD/SCID mice bearing subcutaneous Kras<sup>WT</sup> cells developed pulmonary lesions, while 5 of 8 mice with subcutaneous Kras<sup>G12C</sup> cells developed lung metastases ( $P = 0.0256, \chi^2$ test; Fig. 5D). We next examined HEK293T spots that had grown into tumors for NFkB pathway component immunoreactivity. By immunoblotting, we observed nuclear localization of IKKa but not ΙΚΚβ in control tumors expressing Kras<sup>WT</sup> that was further enhanced by coexpression of IKK  $\beta.$  Kras  $^{\rm G12C}$  tumors showed both IKKα and IKK $\beta$  nuclear immunoreactivity, while *Kras*<sup>G12C</sup>-IKKαexpressing tumors had enhanced IKKa and diminished IKKB nuclear signals, and *Kras*<sup>G12C</sup>-IKKβ-expressing tumors displayed loss of both nuclear signals (Fig. 5E). The nuclear localization of IKKα in *Kras*<sup>G12C</sup>-IKKα coexpressing tumors was also evident on tissue sections by immunofluorescence (Fig. 5F). In addition to KRAS-IKK coexpression in benign cells, we stably expressed shRNAs specifically targeting IKKa and IKKB transcripts (Chuk and *Ikbkb*, respectively) in different lung adenocarcinoma cell lines [LLC, Lewis lung adenocarcinoma cells; and primary lung adenocarcinoma cells derived from urethane-induced lung tumors of *FVB* (FULA) and *C57BL/6* (CULA) mice] bearing wild-type *Kras*<sup>WT</sup> (CULA cells), *Kras*<sup>G12C</sup> (LLC cells), *Kras*<sup>Q61R</sup> (FULA1 and FULA3 cells), or silenced *Kras*<sup>Q61R</sup> (FULA3 cells stably expressing sh*Kras*; refs. 25, 29). Interestingly, IKKα silencing resulted in decreased clonogenic capacity *in vitro* and decreased tumor growth *in vivo* specifically of *KRAS*-mutant tumor cells (Supplementary Fig. 6A–C). Moreover, this effect was not obvious *in vitro*, in line with recent observations on the *in vivo*restricted effects of the oncogene (32). Collectively, these results indicated selective addiction of mutant *KRAS* to IKKα during carcinogenesis, possibly via nuclear IKKα functions reported elsewhere (33, 34).

## Combined targeting of IKKa/IKKB is effective against LADC

We subsequently evaluated the therapeutic potential of our findings using cellular and animal systems tailored to noninvasively monitor tumor growth and NFκB activity. For this, three *KRAS*-mutant LADC cell lines (mouse primary LADC, *Kras*<sup>Q61R</sup>; murine LLC, *Kras*<sup>G12C</sup>; A549 human LADC, *KRAS*<sup>G12S</sup>) were stably transfected with constitutive (pCAG.Luc)




## Figure 5.

IKK $\alpha$  selectively promotes the growth of *KRAS*-mutant cells *in vivo*. HEK293T cells were stably transfected with a constitutive luciferase reporter (pCAG.Luc), followed by plasmids encoding control random sequence (pC), wild-type (peGFP.Kras<sup>WT</sup>), or mutant (peGFP.Kras<sup>G12C</sup>) murine *Kras* in-frame with eGFP, and murine IKK $\alpha$  (p*Chuk*) or IKK $\beta$  (p*lkbkb*) in various combinations. Two million cells were injected at different spots of the skin of *NOD/SCID* mice (*n* = 16), followed by serial spot volume assessment and bioluminescent imaging of spot cell mass. Mice were killed after 6 weeks for assessment of primary spots and lungs for tumorigenicity of the injected cells. **A**, Schematic of *in vivo* competition studies between bioluminescent cells expressing combinations of peGFP.KrasWT, peGFP.KrasG12C, p*Chuk*, and p*lkbkb* and representative bioluminescent images. **B** and **C**, Data summary of spot bioluminescence (**B**) and volume (**C**) of p*C* (gray), p*Chuk* (red), and p*lkbkb* (blue)-expressing cells shown as mean (points), SEM (bars), and two-way ANOVA *P* values. ns, nonsignificant; \*, and \*\*\*: *P* > 0.05, *P* < 0.05, and *P* < 0.001, respectively, for comparisons of the indicated color-matched data points to p*C*-expressing cells at the same time point by Bonferroni posttests. **D**, Representative lung images of mice carrying peGFP.KrasWT (top) and peGFP.KrasG12C (bottom) tumors showing lung metastases of luminescent cells in the latter. **E**, Immunoblots of tumor nuclear and cytoplasmic extracts for NFkB pathway components. **F**, IKK $\alpha$  and IKK $\beta$  immunoreactivity of flank tumor cryosections showing increased immunoreactivity of peGFP.KrasG12C/p*Chuk* tumors for IKK $\alpha$  (arrows). *Rel*, v-rel avian reticuloendotheliosis viral oncogene homolog.

and NF $\kappa$ B-dependent (pNGL) LUC reporters, inducibility of the NF $\kappa$ B reporter was validated, and cells were treated with increasing concentrations of the selective IKK $\beta$  inhibitor TPCA-1 {2-[(aminocarbonyl)amino]-5-[4-fluorophenyl]-3thiophenecarboxamide; ref. 35) or the heat shock protein 90 inhibitor 17-DMAG (alvespimycin; 17-dimethylaminoethylamino-17-demethoxygeldanamycin; refs. 36, 37) that blocks, among other targets, IKK $\alpha$  and IKK $\beta$  function; bioluminescence imaging of live *pCAG.Luc* cells after 48-hour treatments was used to determine cell killing and bioluminescence imaging of live *pNGL* cells after 4-hour treatments was used to determine NF $\kappa$ B inhibition. Intriguingly, 17-DMAG displayed superior efficacy in

IKKα in Lung Adenocarcinoma



#### Figure 6.

Dual blockade of IKK $\alpha$  and IKK $\beta$  is effective against *KRAS<sup>GI2D</sup>*-driven lung adenocarcinoma *in vivo*. Mice harboring a conditional loxP-STOP-loxP.*R26.Luc* allele constitutively expressed in the ROSA locus (LSL.*R26.Luc*) were intercrossed with conditional mice carrying a loxP-STOP-loxP.*KRAS*GI2D allele (LSL.*KRAS*GI2D; all *C57BL*/6). Double transgenic LSL.*KRAS*GI2D;LSL.*R26.Luc* mice (n = 30) received 5 × 10<sup>8</sup> intratracheal PFU Ad-*Cre* and were allocated to daily intraperitoneal treatment with the selective IKK $\beta$  inhibitor TPCA-1 or the dual IKK $\alpha$ /IKK $\beta$  inhibitor 17-DMAG (both at 0.5 mg/kg in 100 µL saline; approximately equivalent to 1 to 2 µmol/L by body volume extrapolation) before (prevention trial; days 14-28 after Ad-*Cre*) or after (regression trial; days 84-112 after Ad-*Cre*) lung adenocarcinoma establishment. Thereafter mice were imaged longitudinally for bioluminescence. **A**, Topology of luminescent *R26.Luc* (green, cytosol) versus *KRAS*G12D-expressing (red, nucleus) cells in this model. **B**, Schematic of experimental time course (boxes, weeks). **C**, Data summary of chest bioluminescence shown as mean (points), SEM (bars), and two-way ANOVA *P* value. \*\*, *P* < 0.01; \*\*\*, *P* < 0.001, respectively, for comparisons of the indicated data points to saline-treated mice at the same time point by Bonferroni posttests. **D**, Representative merged bioluminescent/photographic images with pseudocolor scale showing decreased chest (dashed lines) light emission of 17-DMAG-treated mice at 112 days after Ad-*Cre*.


halting cell proliferation and NFkB activity in all three cell lines compared with TPCA-1, as evident by 4- to 5-fold lower 50% inhibitory concentrations of pCAG.Luc activity (mean  $\pm$  SD: 28  $\pm$ 12  $\mu$ mol/L for 17-DMAG and 114  $\pm$  30 for TPCA-1) and 200- to 1,000-fold lower 50% inhibitory concentrations of pNGL activity (mean  $\pm$  SD: 0.133  $\pm$  0.068  $\mu$ mol/L for 17-DMAG and 62  $\pm$  30 for TPCA-1; Supplementary Fig. S7A–S7E). Based on these results and the data from *NGL* mice with *KRAS*<sup>G12D</sup> tumors (Supplementary Fig. S1), we designed an *in vivo* study where mice with *KRAS*<sup>G12D</sup>mutant LADCs received low doses of either drug tailored to inhibit NFkB activity rather than cell proliferation in both preventive and curative modes. To enable repetitive noninvasive bioluminescent quantification of tumor burden in vivo, mice harboring a conditional loxP-STOP-loxP.R26.Luc allele (LSL.R26.Luc; ref. 18) were intercrossed with LSL.KRAS<sup>G12D</sup> mice (all C57BL/6; ref. 17), vielding a model where CRE-recombination leads to simultaneous KRAS<sup>G12D</sup> and LUC expression (Fig. 6A; ref. 38). LSL. *KRAS*<sup>G12D</sup>;*LSL.R26.Luc* mice (n = 30) received  $5 \times 10^8$  intratracheal PFU Ad-Cre and were allocated to drug treatments during the two distinct phases of NFkB activation identified from LSL. KRAS<sup>G12D</sup>;NGL mice (Supplementary Fig. S1): between days 14 and 28 after Ad-Cre (prevention trial) or between days 84 and 112 after Ad-Cre (regression trial; Fig. 6B). Treatments consisted of 100 µL daily intraperitoneal saline, TPCA-1, or 17-DMAG, both at 0.5 mg/Kg in 100 µL saline, equivalent by body volume extrapolation to maximal in vivo concentrations of 1.79 µmol/L for TPCA-1 and of 0.77 µmol/L for 17-DMAG, far inferior to cytotoxic concentrations (Supplementary Fig. S7). Bioluminescent detection of developing LADC revealed that TPCA-1 had no effect, while 17-DMAG prevention and regression regimens efficiently blocked tumor development compared with controls (Fig. 6C and D). Collectively, these results indicate that 17-DMAG exerts beneficial effects against *KRAS*-mutant LADCs *in vitro* and *in vivo*, even at low doses tailored to inhibit NF $\kappa$ B. On the contrary, a specific IKK $\beta$  inhibitor failed to show any effect, further supporting a druggable addiction of IKK $\alpha$  with mutant *KRAS* in LADC.

#### IKKα in human LADC

The relevance of our findings with human LADC was subsequently addressed. For this, tumor and adjacent normal-appearing lung tissues of 23 patients with LADC were analyzed for *CHUK* and *IKBKB* expression by microarray and of another 35 patients from the same series for IKK $\alpha$  and IKK $\beta$  by immune labeling (26). *CHUK* mRNA was overrepresented in normal-appearing and LADC tissue compared with *IKBKB* mRNA, while the levels of both were not different between normal-appearing and tumor tissue (Fig. 7A). However, using a modified NF $\kappa$ B scoring system that examines staining intensity and localization (10), IKK $\alpha$  protein was significantly overexpressed in LADC compared with both normal-appearing tissues and with IKK $\beta$  (Fig. 7B and C), suggesting its possible involvement in the pathogenesis of human LADC.

# Discussion

We report an actionable requirement for IKK $\alpha$  in *KRAS*mutant LADC. Using chemical and transgenic delivery of *KRAS* mutations to the respiratory tract in combination with NF $\kappa$ B reporter and conditional IKK-deleted mice, we map the patterns of NF $\kappa$ B activation in the lungs and identify the critical role of



#### Figure 7.

IKKα in human lung adenocarcinoma. **A,** Data summary of normalized *CHUK* and *IKBKB* expression in tumor and adjacent normal-appearing lung tissues of 23 patients with lung cancer (43) by microarray. Data are shown as mean (columns), SEM (bars), raw data points (dots), and two-way repeated measures ANOVA *P* value. ns, nonsignificant; \*\*\*, *P* > 0.05 and *P* < 0.001 for the indicated comparisons by Bonferroni posttests. **B,** Data summary of IKKα and IKKβ immunoreactivity of tumor and adjacent normal-appearing lung tissues of 35 patients with lung cancer (43) by immunohistochemistry. Data are shown as mean (columns), SEM (bars), raw data points (dots), and two-way repeated measures ANOVA *P* value. ns, \*\*, and \*\*\*, *P* > 0.05, *P* < 0.01, and *P* < 0.001 for the indicated comparisons by Bonferroni posttests. **C,** Representative IKKα- and IKKβ-immunostained lung and tumor tissue sections showing IKKα-immunoreactive cells (arrows). **D,** Schematic of proposed role of IKKα in *KRAS*-mutant lung adenocarcinoma. Endogenous IKKα activity sporadically prevails over IKKβ signaling across different cell types of the respiratory epithelium of smokers. Upon chemical induction of stochastic *KRAS* mutations across the respiratory field, preexisting IKKα activity fosters the survival of *KRAS*-mutant cells and is therefore addicted to the oncogene, while IKKβ signaling promotes the survival and maintenance of nonmutated cells and IKKβ-dependent cells that suffer *KRAS* mutations are destined to death. This opposing addiction of IKKα activity. **E,** Summary of *in vivo* IKK deletion/targeting experiments shown as mean percentile reduction of lung tumor burden by IKKα- and IKKβ-targeted intervention (lines), SEM (bars), raw data (each dot represents one arm of an experiment), and paired Student *t* test *P* value.

IKK $\alpha$ . We show that IKK $\alpha$  drives LADC through cell-autonomous effects that are specifically exerted in the cellular context of mutant *KRAS*. These findings have implications for human disease, because IKK $\alpha$  is overexpressed in human LADC and oncogenic *KRAS*-IKK $\alpha$  addiction was annihilated by treatment with 17-DMAG.

The findings are novel and important on various counts. First, NF $\kappa$ B activity of *KRAS*-mutant LADC is charted in living mice and is shown to be activated early after *KRAS* mutation induction and late in established LADC. This pattern is in line with observations from smokers at risk for LADC that feature airway epithelial NF $\kappa$ B activation (39) and from patients with established LADC that display oncogenic NF $\kappa$ B activation (10). The results are consistent with the hypothesis that NF $\kappa$ B activation occurs together with field mutagenesis in the respiratory tract, persists in mutated cells, and reappears during clinical manifestation of late disease (40), bearing implications for NF $\kappa$ B-based therapy and prevention (Fig. 7D).

Second, noncanonical together with canonical NF $\kappa$ B pathway components are shown to be activated in *KRAS*-driven LADC. Canonical NF $\kappa$ B signaling is long known to be important in human and experimental LADC (8–10), but activity of the alternative pathway has not been described. This finding is in accord with our previous observations of enhanced *Rel*B activity of tumor cells in human LADC (10) and suggests important roles for alternative NF $\kappa$ B signaling in *KRAS*-driven LADC.

Importantly, IKKa is identified as the critical kinase for oncogenic NFκB activation of KRAS-mutant LADC. IKKα deletion provided beneficial effects in four different mouse models of combined KRAS-driven carcinogenesis and IKK depletion from the respiratory epithelium. In addition, 17-DMAG protected mice from KRAS<sup>G12D</sup>-driven LADC when given early (preventive treatment) or late (regression trial), while the IKK $\beta$ blocker TPCA-1 did not. Although 17-DMAG likely suppresses a spectrum of targets broader than IKK $\alpha$  and IKK $\beta$  (41), inclusively targeting IKKa, utilizing even this nonspecific approach provided superior overall effects in reducing tumor burden compared with IKKβ-specific inhibition (Fig. 7E). We were the first to identify that indirect IKKB blockade via overexpression of dominant-negative IkBa protects mice from urethane-induced LADC (8), a finding thereafter recapitulated in KRAS<sup>G12D</sup>-mutant (9), and tobacco-smoke-induced (14) LADC. Urethane-triggered LADCs were recently genomically characterized and shown to harbor Kras<sup>Q61R</sup>/Kras<sup>G12V</sup> mutations (22), similar to human LADC (42). Based on these findings and results from other tumor types, research and drug discovery focused on IKKB yielding proteasome and IKKB inhibitors (35, 43). However, these provide poor outcomes in human LADC (44) and cause resistance or paradoxical tumor promotion in animal LADC models via myeloid NFkB inhibition, secondary mutation development, and/or enhanced neutrophil-provided IL1B (23, 45, 46). In addition, recent evidence indicates that IKKB might not be the only kinase responsible for oncogenic NFKB activation of KRAS-mutant LADC (47). To this end, TBK1 emerged as a KRAS addiction partner and was found to mediate EGFR-inhibitor resistance (5, 6), while IKKE promoted tumorigenesis together with TBK1 (13). Only one study addressed the role of IKKa depletion together with IKKβ in lung cancer cells *in vitro* and found both kinases to be important (11). Our results identify for the first time the pivotal role of IKK $\alpha$  in *de novo* development of *KRAS*mutant LADC *in vivo* and position the kinase as a marked therapeutic target.

Using in vitro and in vivo competition studies, we determine that IKKa selectively fosters the survival of KRAS-mutant cells and is therefore addicted to the oncogene, while IKKB promotes the survival and maintenance of nonmutated cells. We hypothesize that in a stochastically KRAS-mutated respiratory field, this opposing addiction of IKKα and IKKβ to mutant and wild-type KRAS, respectively, would lead over time via clonal selection to KRAS-mutant LADCs with enhanced IKKa activity (Fig. 7D). This cell-autonomous model is supported by the results from  $\mathit{KRAS}^{\mathrm{G12D}}$  mice (where IKK $\alpha$  was selectively deleted in  $\mathit{KRAS}$ mutant cells) and from HEK293T cells (where IKK/KRAS combinations functioned similarly in vitro and in vivo), notwithstanding the possibility for autocrine IKKα-triggered cytokine networks identified elsewhere (48, 49). To this end, IKKa localized to the nucleus of our murine LADCs, a phenomenon that could enhance gene transcription or repress oncogenes (33, 34). Nuclear IKK $\alpha$  was also present in human LADC, which displayed enhanced nuclear IKKa immunoreactivity. The proposed IKKa function to site independently foster KRAS-mutant cells also emanates from tissue-restricted IKK-deletion studies where IKKα was critical in both airway and alveolar cells, a result of importance given the cellular and histologic diversity of human LADC (50).

Finally, a feasible approach for translation of the findings is explored. Treatment with 17-DMAG was tailored to target NF $\kappa$ B activation of *KRAS*-mutant LADC *in vitro* and was translated to a preclinical study, where it was well tolerated and effective against LADC *in vivo*, both preventively and therapeutically. The efficacy of 17-DMAG and the inefficacy of TPCA-1 strengthen the proposed link between mutant *KRAS* and IKK $\alpha$  and open up new avenues for therapy/prevention of *KRAS*-mutant LADC (1). In summary, we report a requirement for IKK $\alpha$  in *KRAS*-driven LADC, implicate IKK $\alpha$  as a *KRAS* nononcogene addiction partner, and show that targeting IKK $\alpha$  may confer beneficial effects against a currently untreatable disease that is the number one cancer killer in the world.

#### **Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

#### **Authors' Contributions**

Conception and design: M. Papageorgopoulou, T.S. Blackwell, A. Marazioti, G.T. Stathopoulos

Development of methodology: M. Vreka, I. Lilis, M. Papageorgopoulou, G.A. Giotopoulou, M. Lianou, I. Giopanou, M. Spella, T. Agalioti, G.T. Stathopoulos

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Vreka, M. Papageorgopoulou, N.I. Kanellakis, M. Spella, T. Agalioti, V. Armenis, S. Marwitz, F.E. Yull, G.T. Stathopoulos

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Vreka, I. Lilis, M. Papageorgopoulou, G.A. Giotopoulou, M. Lianou, I. Giopanou, N.I. Kanellakis, T. Agalioti, T. Goldmann, S. Marwitz, G.T. Stathopoulos

Writing, review, and/or revision of the manuscript: M. Vreka, M. Papageorgopoulou, T. Goldmann, S. Marwitz, F.E. Yull, A. Marazioti, G.T. Stathopoulos

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Vreka, M. Papageorgopoulou, V. Armenis Study supervision: M. Vreka, T. Goldmann, A. Marazioti, G.T. Stathopoulos Other (provided mouse models used in the study): M. Pasparakis

www.aacrjournals.org

Cancer Res; 78(11) June 1, 2018 2949

#### Acknowledgments

This work was supported by European Research Council 2010 Starting Independent Investigator and 2015 Proof of Concept Grants (260524 and 679345, respectively, awarded to G.T. Stathopoulos), as well as a Research Award by the Hellenic Thoracic Society (awarded to M. Vreka).

The authors thank the University of Patras Center for Animal Models of Disease and Advanced Light Microscopy Cores for experimental support.

#### References

- 1. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras Back in the Ring. Cancer Cell 2014;25:272–81.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505–27.
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.
- 4. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68: 3077-80.
- Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108–12.
- 6. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, et al. An integrin  $\beta_3$ -KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014;16:457–68.
- Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115:2625–32.
- Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, et al. Epithelial NF-kappaB activation promotes urethaneinduced lung carcinogenesis. Proc Natl Acad Sci U S A 2007;104: 18514–19.
- Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104–7.
- Giopanou I, Lilis I, Papaleonidopoulos V, Marazioti A, Spella M, Vreka M, et al. Comprehensive evaluation of nuclear factor-κB expression patterns in non-small cell lung cancer. PLoS One 2015;10: e0132527.
- Bassères DS, Ebbs A, Cogswell PC, Baldwin AS. IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity. Genes Cancer 2014;5:41–55.
- 12. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF- $\kappa$ B signaling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523–6.
- Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008;13:343–54.
- Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010;17:89–97.
- Nottingham LK, Yan CH, Yang X, Si H, Coupar J, Bian Y, et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/ AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 2014;33:1135–47.
- 16. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double fluorescent Cre reporter mouse. Genesis 2007;45:593-605.
- Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243–8.
- Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, Kaelin WG Jr. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2003; 2:297–302.
- Luedde T, Heinrichsdorff J, de Lorenzi R, De Vos R, Roskams T, Pasparakis M. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci U S A 2008;105:9733–38.
- 20. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, et al. Pulmonary autotoxin expression contributes to the

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 29, 2017; revised October 3, 2017; accepted March 22, 2018; published first March 27, 2018.

pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 47:566-74.

- Okubo T, Knoepfler PS, Eisenman RN, Hogan BL. Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. Development 2005;132:1363–74.
- Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2015;517:489–92.
- Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, et al. Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis. Carcinogenesis 2012; 33:859–67.
- Karabela SP, Kairi CA, Magkouta S, Psallidas I, Moschos C, Stathopoulos I, et al. Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. Neoplasia 2011; 13:1143–51.
- Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun 2017;8:15205.
- Marwitz S, Depner S, Dvornikov D, Merkle R, Szczygieø M, Müller-Decker K, et al. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion. Cancer Res 2016;76:3785–801.
- Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008;6:364–671.
- Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004;64:2307–2316.
- Giopanou I, Lilis I, Papaleonidopoulos V, Agalioti T, Kanellakis NI, Spiropoulou N, et al. Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis. Oncoimmunology 2017;6: e1256528.
- Hsia CC, Hyde DM, Ochs M, Weibel ER; ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010;181:394–418
- Chen Y, Vallee S, Wu J, Vu D, Sondek J, Ghosh G. Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol Cell Biol 2004;24:3048–56.
- 32. Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-Specific inhibitor. Cell 2018; 172:578–89.
- Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003;423:659–63.
- Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003;423:655–59.
- Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, et al. Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 2005; 172:962–71.
- Rastelli G, Tian ZQ, Wang Z, Myles D, Liu Y. Structure-based design of 7carbamate analogs of geldanamycin. Bioorg Med Chem Lett 2005;15: 5016–21.

2950 Cancer Res; 78(11) June 1, 2018

IKKα in Lung Adenocarcinoma

- Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010;116:45–53.
- Xia Y, Yeddula N, Leblanc M, Ke E, Zhang Y, Oldfield E, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol 2012;14:257–65.
- Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Gnemmi I, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002; 20:556–63.
- Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997;100:2133–37.
- Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47:505–11.
- 42. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.
- 43. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419–28.

- 44. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 2009;27:4487–91.
- 45. McLoed AG, Sherrill TP, Cheng DS, Han W, Saxon JA, Gleaves LA, et al. Neutrophil-derived IL-1 $\beta$  impairs the efficacy of NF- $\kappa$ B inhibitors against lung cancer. Cell Rep 2016;16:120–32.
- Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, et al. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 2011;1:236–47.
- Van Waes C. Targeting NF-κB in mouse models of lung adenocarcinoma. Cancer Discov 2011;1:200–2.
- 48. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, et al. KrasG12D-induced IKK2/ $\beta$ /NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:105–120.
- Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, et al. An NF-κB pathway- mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 2012;122:1519–28.
- Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244–85.





The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

# IKB Kinase $\alpha$ Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma

Malamati Vreka, Ioannis Lilis, Maria Papageorgopoulou, et al.

Cancer Res 2018;78:2939-2951. Published OnlineFirst March 27, 2018.



Cited articles	This article cites 50 articles, 15 of which you can access for free at: http://cancerres.aacrjournals.org/content/78/11/2939.full#ref-list-1
E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/78/11/2939. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.